GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » PB Ratio

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) PB Ratio : 5.12 (As of May. 10, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-10), MoonLake Immunotherapeutics's share price is $41.97. MoonLake Immunotherapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $8.20. Hence, MoonLake Immunotherapeutics's PB Ratio of today is 5.12.

The historical rank and industry rank for MoonLake Immunotherapeutics's PB Ratio or its related term are showing as below:

MLTX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 59.25
Current: 5.2

During the past 3 years, MoonLake Immunotherapeutics's highest PB Ratio was 59.25. The lowest was 0.00. And the median was 0.00.

MLTX's PB Ratio is ranked worse than
77.71% of 1310 companies
in the Biotechnology industry
Industry Median: 2.505 vs MLTX: 5.20

During the past 12 months, MoonLake Immunotherapeutics's average Book Value Per Share Growth Rate was 553.20% per year.

Back to Basics: PB Ratio


MoonLake Immunotherapeutics PB Ratio Historical Data

The historical data trend for MoonLake Immunotherapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics PB Ratio Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23
PB Ratio
- 8.37 7.37

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 8.37 19.93 5.57 7.18 7.37

Competitive Comparison of MoonLake Immunotherapeutics's PB Ratio

For the Biotechnology subindustry, MoonLake Immunotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MoonLake Immunotherapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's PB Ratio falls into.



MoonLake Immunotherapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

MoonLake Immunotherapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=41.97/8.198
=5.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


MoonLake Immunotherapeutics  (NAS:MLTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


MoonLake Immunotherapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Executives
Matthias Bodenstedt officer: Chief Financial Officer DORFSTRASSE 29, ZUG V8 6300
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge director DORFSTRASSE 29, ZUG V8 6300
Kristian Reich officer: Chief Scientific Officer DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge director, officer: Chief Executive Officer DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il director, 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips director C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier director DORFSTRASSE 29, ZUG V8 6300
Spike Loy director DORFSTRASSE 29, ZUG V8 6300
Kara Lassen director DORFSTRASSE 29, ZUG V8 6300

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Headlines

From GuruFocus